Equities

Elite Pharmaceuticals Inc

ELTP:QBB

Elite Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.6168
  • Today's Change-0.001 / -0.15%
  • Shares traded1.66m
  • 1 Year change+302.48%
  • Beta0.2246
Data delayed at least 15 minutes, as of Nov 22 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Elite Pharmaceuticals Inc grew revenues 65.79% from 34.16m to 56.63m while net income improved 464.56% from 3.56m to 20.11m.
Gross margin44.73%
Net profit margin-8.98%
Operating margin23.00%
Return on assets-8.04%
Return on equity-13.83%
Return on investment-10.06%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Elite Pharmaceuticals Inc fell by 705.59k. Cash Flow from Financing totalled 3.39m or 5.98% of revenues. In addition the company used 3.28m for operations while cash used for investing totalled 809.65k.
Cash flow per share-0.0046
Price/Cash flow per share--
Book value per share0.0443
Tangible book value per share0.0375
More ▼

Balance sheet in USDView more

Elite Pharmaceuticals Inc has a Debt to Total Capital ratio of 16.34%, a higher figure than the previous year's 7.44%.
Current ratio3.52
Quick ratio2.42
Total debt/total equity0.1953
Total debt/total capital0.1634
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.